SII seeks permission for Covovax vaccine phase-3 study of booster dose in adults

DNA Sunday, 27 February 2022
The Drugs Controller General Of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28.

💡 newsR Knowledge: Other News Mentions

Serum Institute of India Serum Institute of India Indian biotechnology and biopharmaceuticals company

SII's Adar Poonawalla makes clarion call for global certification of vaccines

"Multilateral organisations such as the United Nations and the World Trade Organisation should take it upon themselves to harmonise the certification of..

You Might Like

Related news from verified sources

SII provided COVID-19 vaccine at 'cost of cup of tea', saved nearly two-thirds of infant population: Cyrus Poonawala

Serum Institute seeks EUA for Covovax Covid-19 vaccine for 12-17 years age group

The data from two studies on about 2,707 individuals aged 12 to 17 years show Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age...
Zee News

SII seeks permission for phase-3 study of Covid vaccine Covovax as booster dose in adults